Concept
Discussion of Studying the effect of ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in COVID-19 Patients with Hypertension (Wuhan, China)
- The different drug treatments show no difference in the progression of the infection and risk of fatality during hospitalization for COVID-19 patients with hypertension
- Results suggest that COVID-19 patients with hypertension should not discontinue taking ACEIs, ARBs, or other antihypertensive drugs because of infection
- Patients with hypertension became more sick from COVID-19 infection and had higher mortality rates than COVID-19 patients without hypertension
0
1
Updated 2020-07-23
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Discussion of Studying the effect of ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in COVID-19 Patients with Hypertension (Wuhan, China)
Results of Studying the effect of ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in COVID-19 Patients with Hypertension (Wuhan, China)
Stats for COVID-19 Patients with Hypertension (needs date of study)